» Articles » PMID: 34433055

Antibody:CD47 Ratio Regulates Macrophage Phagocytosis Through Competitive Receptor Phosphorylation

Overview
Journal Cell Rep
Publisher Cell Press
Date 2021 Aug 25
PMID 34433055
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer immunotherapies often modulate macrophage effector function by introducing either targeting antibodies that activate Fcγ receptors (FcγRs) or blocking antibodies that disrupt inhibitory SIRPα-CD47 engagement. However, how these competing signals are integrated is poorly understood, raising questions about how to effectively titrate immune responses. Here, we find that macrophage phagocytic decisions are regulated by the ratio of activating ligand to inhibitory ligand over a broad range of absolute molecular densities. Using both endogenous and chimeric receptors, we show that activating:inhibitory ligand ratios of at least 10:1 are required to promote phagocytosis of model antibody-opsonized CD47-inhibited targets and that lowering that ratio reduces FcγR phosphorylation because of inhibitory phosphatases recruited to CD47-bound SIRPα. We demonstrate that ratiometric signaling is critical for phagocytosis of tumor cells and can be modified by blocking SIRPα, indicating that balancing targeting and blocking antibodies may be important for controlling macrophage phagocytosis in cancer immunotherapy.

Citing Articles

Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy.

Krishnamoorthy M, Seelige R, Brown C, Chau N, Nielsen Viller N, Johnson L Front Immunol. 2025; 16:1518787.

PMID: 40078999 PMC: 11897230. DOI: 10.3389/fimmu.2025.1518787.


CD47 prevents Rac-mediated phagocytosis through Vav1 dephosphorylation.

Miller W, Mishra A, Sheedy C, Bond A, Gardner B, Montell D bioRxiv. 2025; .

PMID: 39990418 PMC: 11844498. DOI: 10.1101/2025.02.11.637707.


Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment.

Che Z, Wang W, Zhang L, Lin Z J Pharm Anal. 2025; 15(1):101099.

PMID: 39881799 PMC: 11772969. DOI: 10.1016/j.jpha.2024.101099.


Biochemical and biophysical mechanisms macrophages use to tune phagocytic appetite.

Bond A, Morrissey M J Cell Sci. 2025; 138(1).

PMID: 39749603 PMC: 11828473. DOI: 10.1242/jcs.263513.


CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice.

Frederiksen H, Glantz A, Vols K, Skov S, Tveden-Nyborg P, Freude K Front Genome Ed. 2024; 6:1403395.

PMID: 38863835 PMC: 11165197. DOI: 10.3389/fgeed.2024.1403395.


References
1.
Lu J, Ellsworth J, Hamacher N, Oak S, Sun P . Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding. J Biol Chem. 2011; 286(47):40608-13. PMC: 3220521. DOI: 10.1074/jbc.M111.257550. View

2.
Wakselman S, Bechade C, Roumier A, Bernard D, Triller A, Bessis A . Developmental neuronal death in hippocampus requires the microglial CD11b integrin and DAP12 immunoreceptor. J Neurosci. 2008; 28(32):8138-43. PMC: 6670768. DOI: 10.1523/JNEUROSCI.1006-08.2008. View

3.
Kheir W, Gevrey J, Yamaguchi H, Isaac B, Cox D . A WAVE2-Abi1 complex mediates CSF-1-induced F-actin-rich membrane protrusions and migration in macrophages. J Cell Sci. 2005; 118(Pt 22):5369-79. DOI: 10.1242/jcs.02638. View

4.
Okazawa H, Motegi S, Ohyama N, Ohnishi H, Tomizawa T, Kaneko Y . Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol. 2005; 174(4):2004-11. DOI: 10.4049/jimmunol.174.4.2004. View

5.
Chen L, Sung S, Yip M, Lawrence H, Ren Y, Guida W . Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol Pharmacol. 2006; 70(2):562-70. DOI: 10.1124/mol.106.025536. View